General Clinical Chemistry Analyzers and Accessories
Abcam Apremilast, 5MG
MW 460.5 Da, Purity >98%. Ppotent PDE4 (phosphodiesterase 4) inhibitor (IC₅₀ = 74 nM). It reduces TNF-α production in human synovial cells and significantly suppresses experimental arthritis.
The product is subject to the following: Abcam Restricted Use Statement
Abcam WH-4-023, 5MG
MW 568.7 Da, Purity >98%. Potent and selective inihbitor of the tyrosine kinases Lck and Src with IC₅₀ values of 2 nM for Lck and 6 nM for Src.
The product is subject to the following: Abcam Restricted Use Statement
Abcam BMS-986142, 5MG
MW 572.6 Da, Purity >=98%. BMS-986142 is a potent, selective, and reversible BTK (Bruton's tyrosine kinase) inhibitor (BTK IC₅₀ = 0.5nM; human WB IC₅₀ = 90 nM). BMS-986142 displays robust efficacy in murine models of rheumatoid arthritis (RA), including collagen-induced arthritis (CIA) and collagen antibody-induced arthritis (CAIA).
The product is subject to the following: Abcam Restricted Use Statement
Abcam GSK2656157, 5MG
MW 416.5 Da, Purity >=98%. Potent and selective PERK inhibitor (IC₅₀ = 0.9 nM in cell-free assay). ATP-competitive. Exibits 500-fold selectivity for PERK versus a panel of 300 kinases.
The product is subject to the following: Abcam Restricted Use Statement
Abcam CCG 1423, Rho pathway-mediated signaling inhibitor, 5MG
MW 454.7 Da, Purity >98%. Specific inhibitor of Rho pathway-mediated signaling and activation of serum response factor (SRF) transcription. Displays activity in several in vitro cancer cell functional assays. Potently (<1 mumol/L) inhibits lysophosphatidic acid-induced DNA synthesis in PC-3 prostate cancer cells, inhibits growth of RhoC-overexpressing melanoma lines at nanomolar concentrations. Selectively stimulates apoptosis of the metastasis-prone, RhoC-overexpressing melanoma cell lines. Acts at or downstream of MLK1 and upstream of SRF. Blocks MLK1 nuclear localization.
The product is subject to the following: Abcam Restricted Use Statement
Abcam GNE-0877, 10MG
MW 339.32 Da, Purity =98%. A potent and selective Leucine-rich repeat kinase 2 (LRRK2) inhibitor, Ki = 0.7 nM.
The product is subject to the following: Abcam Restricted Use Statement
Abcam E7820, 5MG
MW 336.4 Da, Purity >=98%. A small molecule sulfonamide derivative with potential antiangiogenic and antitumor activities. E7820 inhibits angiogenesis by suppressing integrin alpha 2, a cell adhesion molecule expressed on endothelial cells. Inhibition of integrin alpha 2 leads to an inhibition of cell-cell interactions, endothelial cell-matrix interactions, vascular endothelial cell proliferation and angiogenesis.
The product is subject to the following: Abcam Restricted Use Statement
Abcam LCL161, 50MG
MW 500.6 Da, Purity >99%. Small molecule SMAC mimetic inhibitor of multiple IAP (Inhibitor of apoptosis) family proteins. (IC₅₀ = 10.23 μM). Inhibits cell proliferation and viability in two human hepatocellular carcinoma cells (Hep3B, IC₅₀ = 10, and PLC5, IC₅₀ = 19).
The product is subject to the following: Abcam Restricted Use Statement
Abcam Alvespimycin (17-DMAG) hydrochloride, 10MG
MW 653.2 Da, Purity >99%. A potent Hsp90 inhibitor (IC₅₀ = 62 nM), can bind to the ATP-binding motif and inhibit the protein chaperoning activity.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Ponesimod, sphingosine-1-phophate receptor agonist, 10MG
MW 461 Da. Ponesimod is a potent agonist of sphingosine-1-phophate receptor. (S1P₁/EDG-1; IC₅₀s = 6, >10,000, 2,068, 1,956, and 142 nM for S1P₁-S1P₅, respectively, in a radioligand binding assay). Selectively activates S1P₁ in a GTPγS assay (EC₅₀s = 5.7, >10,000, 105, 1,108, and 59.1 nM, for S1P₁-S1P₅, respectively).
The product is subject to the following: Abcam Restricted Use Statement
Abcam Ganetespib (STA-9090), 25MG
MW 364.4 Da, Purity >98%. Potent Hsp90 inhibitor (IC₅₀ of 4nM in OSA 8 cells). Causes cytotoxicity in a variety of hematological and solid tumor cell lines by causing degradation of multiple oncogenic Hsp90 client proteins. Ganetespib inhibits MG63 cell lines with IC₅₀ of 43 nM.
The product is subject to the following: Abcam Restricted Use Statement
Abcam 4'-hydro x yazobenzene-2-carbo x ylic acid (HABA), 1G
MW 242.23 Da. An endogenous metabolite. Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement
Abcam BMS-986142, 1MG
MW 572.6 Da, Purity >=98%. BMS-986142 is a potent, selective, and reversible BTK (Bruton's tyrosine kinase) inhibitor (BTK IC₅₀ = 0.5nM; human WB IC₅₀ = 90 nM). BMS-986142 displays robust efficacy in murine models of rheumatoid arthritis (RA), including collagen-induced arthritis (CIA) and collagen antibody-induced arthritis (CAIA).
The product is subject to the following: Abcam Restricted Use Statement
Abcam SIS3, Smad3 inhibitor, 1MG
MW 490 Da, Purity >98%. Potent and selective Smad3 inhibitor. Selectively inhibits TGF-beta 1/ALK5-induced Smad3 phosphorylation. Inhibits the TGF-beta 1 effect on type I procollagen expression at the transcriptional levels via the Smad3-binding site. Has no effect on Smad2, p38, MAPK, ERK or PI 3-kinase signaling.
The product is subject to the following: Abcam Restricted Use Statement
Abcam G10, STING signaling activator, 25MG
MW 430.9 Da, Purity >98%. G10 is an indirect activator or stimulator of interferon genes (STING) signaling. It induces transcription of genes dependent on IRF3 and IFN, which are activated by STING, but has no effect on non-STING activated NF-κB-dependent transcription of IL-8, IL-1β, or MIP-1α in human fibroblasts. However, G10 does increase expression of NF-κB-dependent genes in human peripheral blood mononuclear cells (PBMCs) and human umbilical microvascular endothelial cells (HUMECs). In vitro, it prevents replication of the chikungunya and Venezuelan equine encephalitis alphaviruses (IC₉₀s = 8.01 and 24.57 μM, respectively). G10 (100 μM) increases phosphorylation of IRF3, which is lost in cells lacking STING.
The product is subject to the following: Abcam Restricted Use Statement